The Filing Desk

Shoulder Innovations

SI · NYSE · Health Care · Financials, fiscal 2024 to 2025

SI · Last close · November 19, 2026
$20.31
Value Shoulder Innovations yourself

Shoulder Innovations' revenue rose 49.6% to $47 million in fiscal 2025. Its operating margin was −55.6%, down from −46.3% a year earlier. Free cash flow was −$36 million. The diluted share count rose 13340.5%.

Shoulder Innovations, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 10, 2026 · 0001699350-26-000011 Updated
Revenue
$47M
49.6%
Operating margin
−55.6%
9.2 pts
Net income
−$40M
 
Free cash flow
−$36M
 
Return on equity
−93.8%
 
Market cap
$422M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What Shoulder Innovations does

Shoulder Innovations makes implants and related tools for shoulder replacement surgery. It focuses only on the shoulder. Its main products are InSet anatomic and reverse total shoulder replacement systems, where the replacement parts are designed to sit within the bone. Surgeons use them for patients whose shoulder pain comes from conditions such as arthritis, rotator cuff tears and fractures.

Revenue comes from selling these implant systems to hospitals and ambulatory surgery centers (ASCs), which are outpatient surgical facilities. It sells through its own commercial team and a network of independent distributors. It also offers ProVoyance, a planning tool that uses artificial intelligence to turn CT scans into 3D images so surgeons can plan an operation, and an instrument set that supports both main procedures with two trays. It says it competes in a very competitive business and that its sales depend on hospitals, ASCs, surgeons and patients adopting its products.

The company is early-stage and has a history of net losses. It has a loan agreement with Trinity, whose terms limit what it can do. As of December 31, 2025, it had 75 employees, 72 of them full-time.

Its biggest risks, as it describes them

  • It has a history of net losses and may not reach or sustain profitability.
  • It has a significant amount of debt, and its loan covenants may restrict how it operates.
  • It may need more funding that is not available on acceptable terms.
  • It faces competition, and sales depend on hospitals, surgery centers and surgeons adopting its implants.
  • It relies partly on independent distributors to sell its products.
From Shoulder Innovations's annual report on Form 10-K, filed March 10, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Shoulder Innovations lost money in fiscal 2025: a net loss of $40 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY24FY25
Cash and short-term investments15124
Debt incl. finance leases1515
Net debt (negative means net cash)−0−109
Net debt to EBITDA——
Debt to equity—0.1x
Interest coverage−11.1x−375.7x
Current ratio4.6x11.1x
Quick ratio2.8x9.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Shoulder Innovations' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $214,878 of Shoulder Innovations shares on the open market, and 3 insiders sold $5.5 million, $839,131 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 14, 2026Robert Joseph BallCEO & Executive Chairman, DirectorSold10,175$18.45$187,729Form 4
Aug 26, 2026Gilde Healthcare Holding B.V.10% ownerSold1,196$22.60$27,030Form 4
Aug 24, 2026Gilde Healthcare Holding B.V.10% ownerSold681$22.62$15,404Form 4
Aug 21, 2026Gilde Healthcare Holding B.V.10% ownerSold20,516$22.61$463,867Form 4
Aug 20, 2026Gilde Healthcare Holding B.V.10% ownerSold3,900$22.60$88,140Form 4
Aug 18, 2026Matthew Fraser AhearnChief Operating Officer, DirectorSold plan14,186$20.99$297,759Form 4
Aug 17, 2026Matthew Fraser AhearnChief Operating Officer, DirectorSold plan8,314$20.10$167,111Form 4
Aug 6, 2026Gilde Healthcare Holding B.V.10% ownerSold2,095$22.60$47,347Form 4
Aug 5, 2026Gilde Healthcare Holding B.V.10% ownerSold7,338$22.64$166,132Form 4
Aug 4, 2026Gilde Healthcare Holding B.V.10% ownerSold99,812$22.77$2.3 millionForm 4
Aug 3, 2026Gilde Healthcare Holding B.V.10% ownerSold10,751$22.71$244,155Form 4
Jul 31, 2026Gilde Healthcare Holding B.V.10% ownerSold20,034$22.73$455,373Form 4
The latest 12 of 22 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY25
Piotroski F-score—
Rule of 40−26.5%
Altman Z''7.68
Accruals ratio−11.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY25
Net income is positiveFail
Cash from operations is positiveFail
Return on assets rose—
Cash from operations exceeds net incomePass
Debt fell relative to assets—
Current ratio rosePass
Share count didn't riseFail
Gross margin roseFail
Revenue rose relative to assets—
F-score—
Companies that report no gross profit are scored on the other eight.

Compare

Put Shoulder Innovations side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Shoulder InnovationsFY2549.6%−55.6%−76.1%———
TriSalus Life SciencesFY2553.4%−59.7%−41.9%——3Compare
CarlsmedFY2585.9%−60.5%−58.6%———Compare
SANUWAVE HealthFY2535.0%11.2%4.4%—1.7x—Compare
SS Innovations InternationalFY25105.7%−19.3%−52.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

2 years of figures

Fiscal yearFY24FY25
Income statement
Revenue3247
Revenue growth—49.6%
Gross profit2436
Research and development48
Operating income−15−26
Net income−16−40
Diluted EPS (US$)−242.04−4.65
Diluted shares (millions)09
Cash flow
Cash from operations−14−29
Capital expenditure47
Free cash flow−18−36
Dividends paid00
Share buybacks00
Acquisitions00
Stock-based compensation11
Balance sheet at fiscal year end
Cash and short-term investments15124
Debt incl. finance leases1515
Total assets43170
Total liabilities2329
Shareholders' equity−55141
Margins and ratios
Gross margin77.0%76.5%
Operating margin−46.3%−55.6%
Net margin−49.4%−85.3%
Free cash flow margin−57.4%−76.1%
Rule of 40 (growth + FCF margin)—−26.5%
Return on capital——
Return on equity—−93.8%
Return on assets—−37.9%
Net debt to EBITDA——
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Shoulder Innovations' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Shoulder Innovations.